Deutsche Bank Ups Illumina Stock to Buy | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank Deutsche Bank today upgraded Illumina’s stock to ‘buy’ from ‘hold’ after the company last week reported strong fourth-0quarter revenues but warned of high costs this year.
 
As GenomeWeb News reported last week, Illumina said total revenues for the three months ended Dec. 31, 2006, jumped 163 percent as R&D spending rose 17 percent and profit soared.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.